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Hyperlipidemia is a major risk factor associated with increased risk of 
myocardial infarction. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin are 
a class of oral anti-diabetic drugs with secondary pleiotropic effects on metabolic and 
cardiovascular parameters. This study aimed to determine the possible cardioprotective 
effects of sitagliptin on ischemia-reperfusion (I/R) injury in animals kept on high-fat diet. 
Male Wistar rats were fed with high-fat diet (HF) for 12 weeks, to induce hyperlipidemia. 
During the last two weeks of the feeding period, animals were orally treated with different 
doses of sitagliptin (Sitg: 25, 50, 100, and 150 mg/kg/day), or saline as a control. Heart 
tissues were then isolated and subjected to two different I/R-injury protocols for infarct 
size (IS) measurement and biochemical analysis. To test the role of NOS enzyme, NOS 
inhibitor (L-NAME) was injected intraperitoneally for IS evaluation. As an effective dose, 
Sitg (50 mg) exhibited a significant impact on IS. NOS activity increased significantly in the 
Sitg (50 mg) treated groups; however this protective effect was abolished in the presence 
of L-NAME. The protective effect of Sitg that was mediated by TRP channels in our previ-
ous study on normolipidemic animals was abrogated in animals fed with high-fat diet.


























Hyperlipidemia is considered a major risk factor for 
ischemic heart disease (Kupai et al. 2009) and myocardial 
infarction (MI) (Wu et al. 2013), due to its contribution 
in atherosclerotic plaque formation in coronary vessels, 
accompanied by increase in infarct size (IS) and cardiac 
apoptotic and necrotic death (Ma et al. 2013). 
Experimental studies mostly addressed cardioprotec-
tive effects against ischemia-reperfusion (I/R) injury in 
healthy animal models, in which I/R is imposed in the 
absence of other diseases or risk factors such as hyperlip-
idemia (Kupai et al. 2009). However, studies using diseased 
animal models with high-fat and high-cholesterol diets 
showed a high susceptibility of rodent hearts to I/R injury 
and diminished cardioprotective outcomes (Lauzier et al. 
2009). As the incidence of cardiovascular disorders with 
an increased risk of myocardial infarction continues to 
grow due to dyslipidemia and obesity, and finding new 
and novel therapeutic targets is still a challenge.
Most of the drugs failed to find their way into clini-
cal practice, and no drug has been approved for infarct 
size limitation in patients with acute coronary syndrome 
(Downey and Cohen 2009). Additionally, commonly 
used anti-diabetic drugs against diabetes including di-
peptidyl peptidase-4 (DPP-4) inhibitors, were found to 
be independently associated with pleiotropic effects in 
cardiovascular diseases (Nissen and Wolski 2007). DPP-4 
inhibitors (DPP-4i) are incretin-based drugs that act by 
inhibiting the DPP-4 enzyme, resulting in prolonged 
action of glucagon-like peptide-1 (GLP-1) (Apaijai et al. 
2013). In addition to their glycemic control effect, DPP-
4i has been reported to exert cardioprotective actions in 
high-fat diet (HFD) animal models (Apaijai et al. 2013). 
To the best of our knowledge, only one study addressed 
the effect of sitagliptin on cardiovascular complica-
tions after long-term of HFD consumption (Apaijai et 
al. 2013), without addressing its effect against I/R injury. 
Consequently, the ability of these therapies to reduce the 
deleterious effects of high-fat diet on the cardiovascular 
system are still equivocal (Torekov et al. 2011). 
Endothelial nitric oxide synthase (e-NOS) is consti-
tutively expressed in cardiomyocytes, while hypercho-
lesterolemia was found to be associated with impaired 
endothelial function in coronary circulation (Kuo et 
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al. 1992), lower nitric oxide (NO) production (White 
et al. 1994). Moreover, reduced e-NOS expression was 
observed in heart tissues of hypercholesterolemic rab-
bit model (Onody et al. 2003). The correlation between 
DPP-4 inhibitors and nitric oxide synthase (NOS) system 
was depicted in few studies; however, the potential role 
of NOS remains unclear in ischemic heart. Transient 
receptor potential (TRP) channels including the Canoni-
cal (TRPC) and Vanilloid (TRPV) subfamilies are non-
selective calcium (Ca2+) permeable ion channels (Nilius 
and Droogmans 2001) vastly expressed in sensory nerve 
fibers that innervates the heart, blood vessels and vas-
cular endothelial cells (Shenton and Pyner 2014). These 
channels became the subject of growing research inter-
est over the last decades, due to their disparate effects in 
cardiovascular complications, but their protective effects 
against myocardial I/R injury were scarcely reported 
(Vemula et al. 2014). 
Whether sitagliptin-induced cardioprotection against 
I/R injury can be mediated by NOS and/or TRP channels 
in hyperlipidemia is still unknown. Therefore, in this study 
we aimed to elucidate the possible protective mechanisms 
of sitagliptin against I/R injury and myocardial infarct 
size (IS) in a hyperlipidemic rat model, in comparison 
with the results from normolipidemic animals in our 
previous study (Al-Awar et al. 2018). 
We have previously tested the hypothesis in normolip-
idemic animals (Al-Awar et al. 2018), and we found that 
NOS and transient receptor potential (TRP) channels are 
potent mediators in sitagliptin-induced cardioprotection. 
MATERIALS AND METHODS
Drug preparations
Sitagliptin filmtablets ( Januvia 100 mg, Merck, Hert-
fordshire, UK) were purchased and dissolved in physi-
ological saline solution (0.9%) before each oral treatment 
and according to different intended doses. Tiopental 
(Tiobarbital Braun, 0.5 g, B. Braun Medical USA) was 
dissolved in saline (0.9%) and used as anesthetic agent. 
NOS-inhibitor (Nω-nitro-L-arginine methyl ester hy-
drochloride; L-NAME), purchased from Sigma-Aldrich 
and dissolved in physiological saline (0.9%).
Animals and experimental design
Our study falls within the standards of the European 
Community guidelines for the Care and Use of Labora-
tory Animals. All procedures were performed according 
to the protocols approved by the Institutional Ethical 
Animal Care and Use Committee of University of Szeged, 
with the project identification code and date of approval 
(XX/4801/2015, 15 December 2015). Six to eight-week-
old male Wistar rats (body weight 200-300 g; Toxi-Coop, 
Dunakeszi, Hungary) were obtained and acclimatized for 
one week before the onset of treatments. All animals were 
housed in temperature-controlled animal facility (23 °C) 
that belongs to our lab and maintained with a 12h-12 h 
light-dark cycle with food and water provided ad libitum. 
Animals were fed with standard rat chow mixed with fats 
(High fat = HF) for 12 weeks to induce hyperlipidemia.
Animals were assigned into 3 different experiments:
Experiment 1. To determine the effective dose (kg-1day) 
of sitagliptin (Sitg), animals were randomly divided into 
different groups: (Control (saline), Sitg (25 mg), Sitg (50 
mg), Sitg (100 mg) and Sitg (150 mg)/kg/day; n = 5-10). 
Daily oral treatment with the different doses of Sitg or 
its vehicle (Saline) started at the last two weeks of the 
high fat diet (2.5%) feeding. At the end of the treatment, 
the whole-heart preparation and ischemia-reperfusion 
(I/R) injury protocol was performed. Rats were anesthe-
tized with thiopental (i.p. 100 mg/kg), heart tissues were 
rapidly excised, placed in ice-cold saline (0.9%), mounted 
and ligated through the aorta into the cannula (ex vivo) 
of a modified Langendorff Apparatus, and perfused with 
Krebs buffer (118 mM NaCl, 4.70 mM KCl, 2.50 mM CaCl2, 
1.18 mM MgSO4, 1.18 mM KH2PO4, 5.50 mM glucose 
and 25 mM NaHCO3) than gassed with 95% O2 and 5% 
CO at 37 °C. Hearts were exposed to 10 min perfusion, 
45 min prolonged regional ischemia by the occlusion of 
the left anterior descending (LAD) coronary artery, and 
120 min reperfusion. At the end of reperfusion, the LAD 
Figure 1. Summary of 3 different experimental protocols. (a) Heart 
tissues subjected to 45 min ischemia and 120 min of reperfusion, 
after two weeks of oral treatment with saline and different doses of 
Sitg, for infarct size measurements. (b) Hearts subjected to 45 min 
ischemia and 10 min brief reperfusion for biochemical measurements. 
(c) Infarct size measurement from heart tissues exposed to prolonged 
ischemia-reperfusion injury, after 2-weeks co-treatment with saline or 
Sitg (50 mg), and intraperitoneal injection of NOS-inhibitor (L-NAME).
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coronary artery was religated, and the area at risk (AAR) 
was stained with Evans blue dye via the aortic root. Hearts 
were weighed and stored at -20 oC for further staining 
with triphenyltetrazolium chloride (TTC). In the clini-
cal setting, the importance lies in the dose- protective 
effect of any drug; therefore, we considered the 50 mg 
dose of sitagliptin as the effective dose for biochemical 
measurements (Fig. 1a).
Experiment 2. For in vitro laboratory measurements, 
another set of experiments was carried out, by assigning 
only two animal groups (Control (Saline) and Sitg (50 mg), 
n = 10). At the end of the treatment, same anesthetization 
procedure and whole-heart preparation process were 
carried out as in Experiment 1. Cannulated hearts were 
exposed to 10 min perfusion, 45 min prolonged regional 
ischemia by occluding the LAD coronary artery, followed 
by 10 min brief reperfusion. At the end of the experiment, 
heart tissues were weighed, clamped and stored at -80 oC 
for further biochemical analyses (Fig. 1b).
Experiment 3. To confirm the involvement of NOS in 
Sitg-mediated (50 mg) cardioprotection against IR injury, 
four different animal groups (Control (Saline), Sitg (50 
mg), Control (Saline) + L-NAME, and Sitg (50 mg) + L-
NAME, n = 6-8) were included. The Control (Saline) and 
Sitg (50 mg) animal groups received the same daily oral 
treatment as in Experiment 1, while the other two groups 
were co-treated intraperitoneally (i.p.) with the NOS 
inhibitor (L-NAME, 25 mg/kg/day) ( Jaarin et al. 2015), 
three hours’ post-oral administration of Sitg (50 mg) and 
its vehicle (saline). At the end of the treatment, the same 
anesthetization procedure, whole-heart preparation pro-
cess, and I/R injury protocol (10 min perfusion, 45 min 
prolonged regional ischemia and 120 min reperfusion, 
ex vivo), coronary artery re-ligation, and tissue staining 
procedure were carried out as in Experiment 1 (Fig. 1c).
Tissue staining and infarct size (IS) measurements
At the end of each prolonged reperfusion phase (120 min), 
the LAD coronary artery was re-ligated, and the risk 
zone was stained with Evans blue dye via the aortic root. 
Hearts were frozen, transversely sectioned (5-6 slices, 
2-mm thickness) from the apex to the base, and incubated 
in 1% TTC for 10 min at 37 °C. After incubation, tissue 
sections were fixed for 10 min in 10% formalin and placed 
for 30 min in phosphate buffer (pH 7.4). All sections were 
mounted on glass slides, images were captured with a 
digital camera, and infarcted areas were analyzed using 
an ImageJ 1.34 software. The infarction was analyzed in 
each section by an investigator who was blinded to the 
identity of the sections (Fig. 2).
Serum cholesterol and triglyceride measurements 
After removal of heart tissues, blood samples were taken 
from the abdominal aorta, centrifuged, and serum samples 
were collected in Eppendorf tubes and stored at -20 oC for 
cholesterol (Chol) and triglyceride (TG) measurements. 
Chol and TG reagent kits (Diagnosticum, Hungary) were 
used for both measurements. Quantitative determination 
of cholesterol and triglyceride concentration in serum was 
based on enzymatic colorimetric method (PAP). Standard 
and sample (10 µl) measurements at wavelength 490-550 
nm were carried out in 96-well plates, after 5 min incu-
bation at 37 oC and according to the protocols provided 
in the kit’s manual. Results of both measurements were 
expressed in (mmol/l).
Hepatic cholesterol and triglyceride measurements 
At the end of the treatment and after the animals were 
anesthetized, liver tissues were harvested, rapidly clamped 
in liquid nitrogen and stored at -80 oC. Measured samples 
from liver were homogenized in ice-cold modified phos-
phate buffer saline (PBS) by Ultra-Turrax T25 (13 500 
rpm). Liver supernatants were collected, and the same 
Chol- and TG-kits (Diagnosticum, Hungary) were used 
with some modifications in the provided protocols re-
garding dilutions and sample volume. Obtained results 
were expressed in mmol/l.
Figure 2. Representative photographs of transversely-sectioned, 
Evans-blue perfused and TTC-stained heart tissues outlining the area 
at risk (AAR; sum of white and red area); blue, healthy viable tissue; 
and pale white, infarcted tissue. Myocardial infarct area (IS; white) was 
measured post-myocardial ischemia-reperfusion and TTC staining, in 




Cardiac DPP-4 activity was measured in Control (Saline) 
and Sitg (50 mg) treated groups, using a DPP-4 activity 
assay kit and according to the manufacturer’s guidelines 
(Sigma-Aldrich, St. Louis, USA). Ten mg of heart tissue 
were homogenized in ice-cold DPP-4 Assay Buffer, cen-
trifuged at 13 000 g for 10 min (4 °C), after which super-
natants were collected. Standard and sample fluorescence 
intensity (FLU) measurements (λex = 360 nm / λem = 460 
nm) were carried out after 5-min incubation at (37 oC) 
in 96-well black plates designed for fluorescence assays, 
using a fluorescence multi-well plate reader. Incubation 
and measuring cycles were repeated until the most ac-
tive sample was near to or greater than the value of the 
highest standard (100 pmol/well). Results were expressed 
as microunit/ml.
Nitric oxide synthase (NOS) activity
NOS activity was measured by quantifying the con-
version of [14C]-labeled L-arginine to citrulline by a 
previously described method with some minor modi-
fications (Boughton-Smith et al. 1993). Heart tissues 
were homogenized with Ultra-Turrax T25 (13 500 rpm; 
twice for 30 sec) in ice-cold buffer containing 10 mM 
N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] 
(HEPES), 32 mM sucrose, 1 mM dithiothreitol (DTT), 
0.1 mM EDTA, 10 μg/ml soybean trypsin inhibitor, 10 
μg/ml leupeptin, and 2 𝜇g/ml aprotinin, at pH 7.4 (all 
chemicals were from Sigma-Aldrich, Budapest, Hun-
gary). Supernatants were collected after centrifugation 
(20 000 g, 30 min, 4 °C). Samples (40 μl) were incubated 
for 10 min at 37 °C with 100 μl of assay buffer (50 mM 
KH2PO4, 1.0 mM MgCl2, 50 mM L-valine, 0.2 mM 
CaCl2, 1.0 mM dithiotreitol (DTT), 1.0 mM L-citrulline, 
15.5 nM L-arginine, 30 μM flavin adenine dinucleo-
tide, 30 μM flavin mononucleotide, 30 μM tetrahydro-
L-biopterin dihydrochloride, 450 μM β-nicotinamide 
adenine dinucleotide phosphate (β-NADPH), and 12 
pM [14C]-L-arginine monohydrochloride (all chemicals 
were from Sigma-Aldrich). Reactions were terminated 
by the addition of 0.5 ml of a 1:1 (v/v) suspension of ice-
cold DOWEX (Dowex 50WX8 hydrogen form 100-200 
mesh, Sigma Aldrich) prepared in distilled water. The 
mixture was resuspended by adding 850 μl of ice-cold 
distilled water, and 970 μl of supernatant was removed 
for determination of radioactivity by scintillation count-
ing. Ca2+ dependence of NOS activity was determined 
by adding 10 μl of ethylene glycol-bis (β-aminoethyl 
ether) tetraacetic acid (EGTA; 1 mM, Sigma-Aldrich). 
NOS activity was confirmed by inhibition with 10 μl 
of Nω-nitro-L-arginine methyl ester (L-NNA; 3.7 mM, 
Sigma-Aldrich). The level of inducible NOS (i-NOS) 
was defined as the extent of citrulline formation that 
was inhibited by L-NNA, but not by EGTA. Constitutive 
NOS (cNOS) activity was calculated from the difference 
between the extent of citrulline formation inhibited by 
EGTA and the total activity. As the nature of the cNOS 
isoform (e-NOS or n-NOS) was not determined, this ac-
tivity is referred to as cNOS. NOS activity was expressed 
as pmol/min/mg protein.
ELISA measurements (GLP-1, TRPV-1 and CGRP)
Double-antibody sandwich ELISA kits for rat GLP-1, 
TRPV-1 and CGRP measurements were purchased from 
SunRed Biotechnology (Shanghai, China). The same 
homogenization procedure (Ultra-Turrax T8, 20 min 
centrifugation at 2000-3000 rpm) was followed, using the 
PBS homogenization buffer (pH 7.2-7.4). Tissue sample 
preparation procedure was done on ice. The three pa-
rameters were measured according to the manufacturer’s 
protocols, and optical densities (OD) were determined at 
450 nm wavelength. Results are expressed in ng/ml for 
GLP-1 and TRPV-1 and ng/mg protein for CGRP.
Calcium (Ca2+) content test
A colorimetric Calcium Detection Assay Kit (Abcam, 
Cambridge, UK) was used to determine the calcium (Ca2+) 
concentration. Samples were homogenized on ice using 
PBS + 0.1% NP-40 and centrifuged at a maximum speed 
(15 300 rpm) for 2-5 min at 4 o C. Measurements from 
supernatants were performed according to the provided 
procedure. OD were measured (λ = 575 nm) and results 
were expressed in ng/mg protein.
CD26 (DPP-4), TRPC-1 and e-NOS protein expression by 
Western blotting normalized to β-actin
Measured heart tissues were homogenized by Ultra-
Turrax T25 (13 500/s; twice for 30 sec) with ice-cold radio 
immunoprecipitation assay (RIPA) buffer (containing a 
protease inhibitor and TRITON-X-100), for CD26 (DPP-
4) and TRPC-1 proteins, and Homo-buffer (containing 
phosphatase inhibitor, vanadate (1:50)), for e-NOS. Ho-
mogenates were centrifuged (12 000 rpm, 10-15 min, 4 
°C). Proteins were separated by an 8% and 10% sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE, 1 mm gel cassette), and transferred into nitrocel-
lulose membranes. Blots were probed overnight (4 oC, 
and 1% milk) with anti-TRPC-1 rabbit primary antibody 
(1:500, ab192031, Abcam), and anti- eNOS mouse primary 
antibody (1:250, ab 76198, Abcam), respectively, 2 hours 
at room temperature with anti-CD26 rabbit primary 
antibody (1:500, ab129060, Abcam), and anti-beta actin 
mouse primary antibody (1% BSA, 1:4000, ab 8226. Ab-
cam). Membranes were then incubated for 1 h at room 
temperature with secondary anti-rabbit antibody (1:1000, 
sc-2370, Santa Cruz, TX, USA), secondary anti-mouse an-
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tibody (1:5000, A9044, Santa Cruz), secondary anti-rabbit 
(1:5000, sc-2370, Santa Cruz), and secondary anti-mouse 
antibody (1:2000, A9044, Santa Cruz) for TRPC-1, e-NOS, 
CD26 and β-actin, respectively. Secondary antibodies 
were conjugated with horseradish peroxidase (HRP) 
enzyme. Signals were developed using an enhanced 
chemiluminescent substrate for detection of HRP (ECL 
Western Blotting Substrate, Thermo Scientific, Rockford, 
USA) and exposed to Hyperfilm. Films and protein band 
densities were analyzed using the Image Quant Software 
(Amersham Pharmacia, Buckinghamshire, UK) after 
scanning with Gel Analyst 3.01 Software (Iconix, Toronto, 
Canada), and were normalized to housekeeping protein 
β-actin (Fig. 3).
Protein determination
Aliquots (20 μl) from diluted samples (15- or 25-fold with 
distilled water) were mixed with 980 μl of distilled water 
and 200 μl of Bradford reagent was added to each sample. 
After mixing and 10-min of incubation, samples were 
assayed spectrophotometrically in a microplate reader 
at 595 nm with a commercial protein assay kit (Bio-Rad, 
Budapest, Hungary). Protein levels were expressed as mg 
protein/ml.
Statistical analysis
All data are shown as Mean ± standard error of mean 
(SEM). Statistical comparisons were performed with 
Student’s two-tailed unpaired t test, one-way ANOVA 
multiple comparison test (Bonferroni), and two-way 
ANOVA, when necessary. Differences were considered 
significant when P< 0.05.
RESULTS
DPP-4i decreased infarct size (IS) in heart tissues of Sitg 
(50 mg) group
Two weeks following the daily oral administration of 
different doses of the same DPP-4 inhibitor (Sitg), Sitg 
treatment (50 mg/kg) resulted in a significant decrease in 
IS (19.99 ± 2.44%) compared to the control group (38.11 
± 1.82%), after 45 min of regional ischemia and 120 min 
of reperfusion. The area of infarction is expressed as the 
percentage of infarct size over the area at risk (Fig. 4).
Serum cholesterol and triglycerides concentration
Cholesterol measurements from serum samples revealed 
significant increase in high-fat diet animals (HF + saline; 
2.72 ± 0.15 mmol/l) compared to normal control animals 
(Saline; 1.95 ± 0.17 mmol/l). Sitagliptin administration 
(HF + Sitg (50 mg)) failed to reduce cholesterol levels (2.75 
± 0.10 mmol/l) when compared to control animal group 
kept on high-fat diet (HF + saline; 2.72 ± 0.15 mmol/l). 
Results are shown in Fig. 5a.
Similarly, serum triglyceride level was significantly 
increased in HF + saline vs. Control (saline); 2.12 ± 0.13 
Figure 3. Protein expression of CD26 (DPP-4), TRPC-1 and e-NOS (a, b 
and c, respectively) in heart tissues from Sitg-treated (50 mg) group, 
compared to the Control (saline) group.
Figure 4. Effect of different doses of Sitg on infarct size (expressed in 
%). Results are shown as Mean ± SEM; n = 5-10 animals/group. Statisti-
cal significance is represented as: *P < 0.05 compared to the Control 
group, and ##P < 0.01 comparing HF + Sitg (50 mg) and HF + Sitg (150 
mg) groups together. Sitg (50 mg) exhibited a significant decrease in 
infarct size, while no significance was observed in other doses (25, 
100, and 150 mg).
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vs. 0.72 ± 0.04 mmol/l. In addition, no significant decrease 
was observed in triglyceride level in sitagliptin-treated 
group kept on high-fat diet (HF + Sitg (50 mg); 2.09 ± 
0.14 mmol/l) (Fig. 5b). 
Serum cholesterol and triglyceride concentration
Measurements from liver homogenates showed a sig-
nificant decrease in cholesterol level in HF + Sitg (50 
mg) group compared to both the HF + saline group (2.64 
± 0.03 vs. 2.94 ± 0.04 mmol/l), and the absolute (ABS) 
control group (2.64 ± 0.03 vs. 2.86 ± 0.04), respectively. 
However, no change in cholesterol profile was reported 
when comparing the HF + saline group (2.924 ± 0.044 
mmol/l) to the ABS control group (2.982 ± 0.146 mmol/l) 
(Fig. 6a). On the contrary, liver triglyceride exhibited a 
significant increase in animals kept on high-fat diet (HF 
+ saline; 1.73 ± 0.03 mmol/l), compared to the absolute 
control group (ABS control; 1.59 ± 0.03 mmol/l). On the 
other hand, no significant difference in hepatic triglyc-
eride was observed in high-fat diet group treated with 
sitagliptin (HF + Sitg (50 mg)) compared to high-fat diet 
control group (HF + saline), (1.65 ± 0.04 mmol/l vs. 1.73 
± 0.03 mmol/l) (Fig. 6b).
Effect of Sitg on heart tissue DPP-4 activity and GLP-1 
level 
Measurements from heart tissues subjected to brief re-
perfusion (10 min) showed no significant change in 
GLP-1 levels (8.72 ± 0.76 ng/ml vs. 7.21 ± 0.67 ng/ml) 
and DPP-4 activity (5.41 ± 0.95 microunits/ml x 102 vs. 
3.64 ± 0.95 x 102), in sitagliptin-treated groups compared 
to Controls (Fig. 7).
Sitg (50 mg) normalized high DPP-4 level in heart tissues 
and aortas of control group
Heart tissues (Fig. 8a) and aortas (Fig. 8b) exhibited a 
significant reduction in DPP-4 level (0.87 ± 0.09 vs. 1.22 
± 0.12 ng/mg protein) and (6.13 ± 0.55 vs. 8.52 ± 0.34 
ng/mg protein), respectively, in Sitg (50 mg) group vs. 
Control (saline). 
Effect of DPP-4i treatment on DPP-4 protein expression 
No significant difference in DPP-4 (CD26) protein ex-
pression was noticed in HF + Sitg (50 mg) group (554.17 
Figure 5. Serum cholesterol (a) and triglyceride (b) levels (expressed in 
mmol/l) in control animals kept on normal or high-fat diet, and high-
fat diet animals treated with sitagliptin. Data are presented as Mean 
± SEM; n = 5-8 animals/group. One-way ANOVA multiple comparison 
test (Bonferroni) was used for statistical analysis, and results were 
considered significant when *P < 0.05.
Figure 6. Liver cholesterol (a) and triglyceride (b) levels expressed in 
mmol/l. Results are considered significant when *P < 0.05. Data are 
presented as Mean ± SEM (n = 4-5 animals/group).
Figure 7. Ischemic cardiac tissue GLP-1 level and DPP-4 activity after 
two weeks oral treatment with Sitg (50 mg). Results are expressed in ng/
ml and microunits/ml x 102, for GLP-1 and DPP-4 activity, respectively. 
Presented data are presented as Mean ± SEM (n = 4-10 animals/group).
Figure 8. Changes in DPP-4 level (expressed in ng/mg protein) in heart 
tissues (a) and aorta (b) of Sitg (50 mg) treated animal group (HF + Sitg 
(50 mg)), compared to Control (HF + saline). Data are presented as 
Mean ± SEM (n = 5-7 animals/group). Statistical significance: *P < 0.05 
compared to the control group.
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± 136.91 intensity x mm2) vs. HF + Control (saline) group 
(581.03 ± 121.71 intensity x mm2), after normalization to 
β-actin (Fig. 3a and 9).
DPP-4i increased CGRP but not TRPV-1 levels 
No marked change in heart TRPV-1 level was observed 
in Sitg-treated (50 mg) group (4.08 ± 0.28 ng/ml x 10) 
compared to the Control (5.23 ± 0.31 ng/ml x 10). CGRP 
level was augmented in Sitg (50 mg) group (16.65 ± 1.04 
ng/mg protein) vs. Control group (10.93 ± 1.84 ng/mg 
protein) (Fig. 10).
Enhanced cardiac calcium (Ca2+) content in Sitg-treated 
(50 mg) group
To determine whether sitagliptin impacts calcium con-
centration of the ischemic myocardium in hyperlipid-
emic state, a colorimetric calcium detection assay was 
used. Results showed non-significant change in calcium 
content in heart tissues subjected to drug therapy (61.52 
± 13.51 ng/mg protein) vs. Controls (22.79 ± 6.53 ng/mg 
protein) (Fig. 11).
TRPC-1 protein expression level
The difference in TRPC-1 protein expression level be-
tween the Control (HF + saline) and HF + Sitg (50 mg) 
treated groups is presented in Figures 12 and 3b. Unlike 
the results from normolipidemic animals (Al-Awar et 
al. 2018), Sitg-treated (50 mg) group exhibited a slight 
non-significant decrease (752.19 ± 40.11 intensity x mm2) 
in TRPC-1 expression in comparison with the Control 
group (862.77 ± 143.44 intensity x mm2).
Figure 9. DPP-4 protein expression level (expressed in intensity x 
mm2) in heart tissues of HF + Sitg (50 mg) group (n = 6), compared to 
control group (HF + Saline; n = 5) group. Data are presented in term 
of Mean ± SEM.
Figure 10. Effect of 50 mg dose of Sitg on cardiac TRPV-1 and CGRP 
levels, after two weeks oral treatment. Data are illustrated as Mean ± 
SEM; (n= 4-9 animals/group).
Figure 11. Changes in cardiac calcium content of the Sitg (50 mg) 
treated animals, compared to the control ones. Values are in terms 
of Mean ± SEM.
Figure 12. Unaffected TRPC-1 protein expression level (intensity x 
mm2) in heart tissues of HF + Sitg (50 mg) treated group (n = 8) vs. 
Control group (HF + saline; n = 8). Data are presented as Mean ± SEM.
Al-awar et al.
187
DPP4-i upregulated cNOS activity and e-NOS protein 
expression in heart tissues of Sitg (50 mg)
cNOS activity
Two weeks of daily treatment with Sitg (50 mg), followed 
by excision of heart tissues and brief reperfusion (45 min 
occlusion and 10 min reperfusion) of the coronary artery, 
lead to a significant increase in cNOS activity (96.51 ± 
13.75 pmol/min/mg protein), compared to the Control 
group (52.38 ± 11.56 pmol/min/mg protein) (Fig. 13).
e-NOS protein expression
Expression of endothelial nitric oxide synthase (e-NOS) 
as determined by Western blot is shown in Figures 3c and 
14. The level of expression was insignificantly changed 
in HF + Sitg (50 mg) treated animals (470.32 ± 73.79 
intensity x mm2), compared to the Controls (425.26 ± 
31.77 intensity x mm2).
Effect of L-NAME on NOS-mediated cardioprotection 
against infarct size 
The implication of NOS in DPP-4 inhibition-induced 
cardioprotection was confirmed by treating the animals 
with NOS-inhibitor (L-NAME) and measuring the size 
of infarction. The current results are in line with the 
previous work in normolipidemic animals, showing 
a significant reduction (18.47 ± 1.22%) in Sitg (50 mg) 
group, compared to Control (HF + saline) group (43.33 
± 1.86%). However, this protective effect was lost in HF 
+ Sitg (50 mg) + L-NAME group (59.17 ± 6.09%) when 
compared to the results obtained from animals treated 
with Sitg (50 mg) without L-NAME (HF + Sitg (50 mg); 
18.47 ± 1.22%) (Fig. 15).
DISCUSSION
DPP-4 inhibitors were extensively studied in healthy 
animal models as a remedy for cardiovascular disorders; 
however, the interventional mechanisms of the latter 
drugs were poorly addressed in diseased models, such 
as hyperlipidemia. This study was carried out with the 
aim of extending the results of previous work in normo-
lipidemic animals (Al-Awar et al. 2018). In this HF rat 
model, the effect of hyperlipidemia on the development 
of myocardial infarction (MI) following a temporary 
coronary occlusion (ischemia-reperfusion injury) was 
studied. We hypothesized that hypercholesterolemia can 
be associated with increased infarct size, and sitagliptin 
can decrease its detrimental effect on the heart, clarifying 
mechanisms underlying this protection. 
Treatment with Sitg (50 mg) showed a significant 
decrease in infarct size and increase in cNOS activity in 
comparison with the control group, while this infarct 
size- limiting effect was abolished after NOS-inhibition 
by L-NAME, similarly as in normolipidemic animals 
(Al-Awar et al. 2018). L-NAME is a non-selective NOS 
inhibitor that inhibits the 3 NOS isoforms: endothelial 
NOS (e-NOS), inducible NOS (i-NOS) and neuronal NOS 
(n-NOS). According to a previous study, NOS inhibition 
also blocked its protective effect against myocardial infarct 
size in high-fat diet-fed animal model (Ding et al. 2015). 
Sitagliptin exhibited a lowering effect in liver choles-
terol, but not in liver triglycerides. Moreover, no signifi-
cant change was observed in serum Chol and TG levels 
in animal groups treated with Sitg (50 mg), compared 
to the controls. According to previous clinical studies, 
treatment with 50 mg dose of sitagliptin was effective 
in lowering lipid profile and glucose levels, and reducing 
DPP-4 activity by approximately 80% in patients with type 
2 diabetes (Herman et al. 2005; Shigematsu et al. 2014)
Figure 13. Significant increase (*P < 0.05) in constitutive nitric oxide 
synthase (cNOS) activity in heart tissues of HF + Sitg (50 mg) group (n = 
7), compared to Control group (HF + saline; n = 7). Values are expressed 
in pmol/min/mg protein.  Data are presented as Mean ± SEM.
Figure 14. Unaffected level of e-NOS expression (expressed in Intensity 
x mm2) in heart tissues of HF + Sitg (50 mg) group (n = 8), compared to 
Control group (HF + saline; n = 6). Data are presented as Mean ± SEM.
Effect of sitagliptin against ischemia/reperfusion injury
188
In the contrary of obtained findings from normo-
lipidemic animals (Al-Awar et al. 2018), the expected 
decrease in DPP-4 activity and increase in GLP-1 was 
not observed in high-fat diet condition. However, treat-
ment with sitagliptin exhibited a significant decrease 
in DPP-4 protein level measured from heart tissues and 
aortas. Taking into consideration the dietary factor alone, 
a significant increase in GLP-1 level can be observed in 
hyperlipidemic (Control (HF + saline)) group compared 
to the normolipidemic (Control (Saline)) group, making 
high-fat diet a suspicious factor in blocking the protective 
effect of sitagliptin. 
On the level of protein expression, results revealed no 
remarkable change in CD26, e-NOS and TRPC-1 protein 
levels, comparing the Sitg-treated groups to Control ones. 
On the other hand, a significant increase in e-NOS and 
TRPC-1 expression was observed in animals kept on nor-
mal diet and treated with sitagliptin (Al-Awar et al. 2018). 
It was previously suggested that hypercholesterolemia 
can partially block the ion channels and its membrane 
receptor downstream signaling by reducing membrane 
fluidity, leading to cardiomyocyte dysfunction (Wu et al. 
2017). This blockage might be also evident in the current 
study, because the protective effect of Sitg shown to be 
mediated by TRPV/TRPC upregulation in normolipidemic 
animals, was lost after a long-term consumption of high 
fat- diet. Obtained results from CGRP measurement are 
in line with the results obtained from animals fed with 
standard diet (Al-Awar et al. 2018). This suggests that 
Sitg can have a direct effect on CGRP in hyperlipidemic 
condition, independently from TRP channels.
Based on the obtained results of infarct size analysis, 
we extended our experiments to study the mechanisms 
and biochemical markers underlying the Sitg (50 mg) dose. 
We studied the effect of sitagliptin in an ex vivo I/R injury 
model. However, investigating the same drug using an in 
vivo I/R injury model can support the protective effects 
and clinical relevance of sitagliptin.
Conclusions
Sitagliptin was effective in lowering the infarct size (IS) 
and upregulating nitric oxide synthase (NOS). However, 
its protective effect mediated by transient receptor po-
tential (TRP) channels in normolipidemic animals was 
abolished under hyperlipidemic condition. 
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